These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11051641)

  • 21. Development of a standardised multidrug-resistant/extensively drug-resistant tuberculosis assessment and monitoring tool.
    Migliori GB; Sotgiu G; Jaramillo E; Mirzayev F; Centis R; Colvin C; Richardson MD
    Int J Tuberc Lung Dis; 2009 Oct; 13(10):1305-8. PubMed ID: 19793438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of acquired MDR-TB and HIV co-infection.
    Deivanayagam CN; Rajasekaran S; Venkatesan R; Mahilmaran A; Ahmed PR; Annadurai S; Kumar S; Chandrasekar C; Ravichandran N; Pencillaiah R
    Indian J Chest Dis Allied Sci; 2002; 44(4):237-42. PubMed ID: 12437236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for drug resistant tuberculosis in southeast Turkey.
    Tanrikulu AC; Hosoglu S; Ozekinci T; Abakay A; Gurkan F
    Trop Doct; 2008 Apr; 38(2):91-3. PubMed ID: 18453496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new approach to treating patients with MDR-TB?
    Iseman MD
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1037. PubMed ID: 12546109
    [No Abstract]   [Full Text] [Related]  

  • 26. [Primary drug resistance of Mycobacterium tuberculosis in patients with new-onset destructive pulmonary tuberculosis].
    Zinov'ev IP; Esaulova NA; Novikov VG; Kokovikhina IA
    Probl Tuberk Bolezn Legk; 2009; (4):37-9. PubMed ID: 19514452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend.
    Rajasekaran S; Chandrasekar C; Mahilmaran A; Kanakaraj K; Karthikeyan DS; Suriakumar J
    J Indian Med Assoc; 2009 May; 107(5):281-2, 284-6. PubMed ID: 19886382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
    Migliori GB; Lange C; Girardi E; Centis R; Besozzi G; Kliiman K; Ortmann J; Matteelli A; Spanevello A; Cirillo DM;
    Clin Infect Dis; 2008 Mar; 46(6):958-9. PubMed ID: 18288911
    [No Abstract]   [Full Text] [Related]  

  • 29. Mycobacteria: treatment approaches and mechanisms of resistance.
    Frothingham R
    J Med Liban; 2000; 48(4):248-54. PubMed ID: 11214197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The clinical features of tuberculosis in children and adolescents excreting drug-resistant Mycobacterium tuberculosis strains].
    Bekembaeva GS; Serikbaeva KS; Kastypkaeva DV
    Probl Tuberk Bolezn Legk; 2009; (6):13-6. PubMed ID: 19642567
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug-resistant tuberculosis in Yangon, Myanmar.
    Phyu S; Lwin T; Ti T; Maung W; Mar WW; Shein SS; Grewal HM
    Scand J Infect Dis; 2005; 37(11-12):846-51. PubMed ID: 16308219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Some epidemiological and clinical aspects of primary resistance to the classic drugs in patients with pulmonary tuberculosis].
    Zierski M
    Tuberkuloza; 1966; 18(1-3):300-6. PubMed ID: 16296101
    [No Abstract]   [Full Text] [Related]  

  • 33. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-resistant tuberculosis in Cuba. Results of the three global projects.
    Montoro E; Lemus D; Echemendía M; Armas L; González-Ochoa E; Llanes MJ; Valdivia JA
    Tuberculosis (Edinb); 2006; 86(3-4):319-23. PubMed ID: 16569512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isoniazid resistant TB and non-compliance.
    van Altena R; van Soolingen D; van der Werf TS
    Thorax; 2004 Dec; 59(12):1098; author reply 1098-9. PubMed ID: 15563712
    [No Abstract]   [Full Text] [Related]  

  • 36. New generation methods for drug susceptibility testing for tuberculosis.
    Katoch VM
    Indian J Tuberc; 2008 Apr; 55(2):61-3. PubMed ID: 18516820
    [No Abstract]   [Full Text] [Related]  

  • 37. A community-based TB drug susceptibility study in Mimika District, Papua Province, Indonesia.
    Kelly PM; Ardian M; Waramori G; Anstey NM; Syahrial H; Tjitra E; Bastian I; Maguire GP; Lumb R
    Int J Tuberc Lung Dis; 2006 Feb; 10(2):167-71. PubMed ID: 16499255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
    Gupta R; Raviglione MC; Espinal MA
    Int J Tuberc Lung Dis; 2001 Dec; 5(12):1078-9. PubMed ID: 11769764
    [No Abstract]   [Full Text] [Related]  

  • 39. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy.
    Escudero E; Peña JM; Alvarez-Sala R; Vázquez JJ; Ortega A
    Int J Tuberc Lung Dis; 2006 Apr; 10(4):409-14. PubMed ID: 16602405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.